Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Evaxion Biotech ( (EVAX) ) is now available.
On November 7, 2025, Evaxion A/S announced new immune data from its phase 2 trial of the AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The data, which builds on previous clinical efficacy results, highlights the vaccine’s ability to induce specific immune responses in patients with advanced melanoma when used in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®. This development further strengthens EVX-01’s data package and underscores its potential impact on cancer treatment, drawing significant interest from the medical community.
The most recent analyst rating on (EVAX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by its strong earnings call performance, highlighting significant strategic achievements and financial improvements. However, financial performance remains a concern due to ongoing losses and reliance on debt. Technical indicators show positive momentum, but valuation metrics reflect challenges in profitability.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a clinical-stage TechBio company based in Denmark, specializing in developing AI-Immunology™ powered vaccines. The company leverages its proprietary AI platform to create novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion is focused on transforming patient care through innovative and targeted treatment options, with a pipeline that includes both oncology and infectious disease vaccines.
Average Trading Volume: 1,594,055
Technical Sentiment Signal: Sell
Current Market Cap: $35.75M
Find detailed analytics on EVAX stock on TipRanks’ Stock Analysis page.